Wegovy demand outruns supply within a year of launch

Less than a year after Wegovy reached US pharmacies, federal regulators formally recognized that Novo Nordisk could not keep up with demand. FDA approved Wegovy (semaglutide) in June 2021 under NDA 215256 and added it to the agency's drug shortage list on March 31, 2022 ^[1]. The company's other semaglutide injection, Ozempic — approved in December 2017 for type 2 diabetes — followed onto the list on August 23, 2022 ^[1].

Those two dates mark the start of a supply gap that lasted nearly three years. FDA did not declare the semaglutide injection shortage resolved until February 21, 2025 ^[1].

What "shortage" actually means

FDA uses a specific legal definition. A shortage is "a period of time when the demand or projected demand for the drug within the United States exceeds the supply of the drug" ^[1]. The agency is required by law to keep an up-to-date public list of drugs it has determined are in shortage, including the drug names, National Drug Code numbers, the applicant's name, the reason for the shortage, and the estimated duration ^[1].

Importantly, FDA evaluates supply and demand nationally — "across the entire market, not at the local level" ^[1]. The agency has acknowledged that even after a shortage is considered resolved, "patients and prescribers may still see intermittent localized supply disruptions as products move through the supply chain from the manufacturer, to wholesalers and distributors, and to local pharmacies" ^[1].

At the time Wegovy was listed, the approved pen strengths were 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL and 2.4 mg/0.75 mL, all single-dose prefilled pen-injectors with an integrated needle ^[1]. FDA has not published, in the order reviewed here, the specific manufacturing reason behind the 2022 Wegovy shortage or month-by-month prescription numbers, so those details are not established by this record.

The knock-on effects

Being on the shortage list did more than signal scarcity. Under the Federal Food, Drug, and Cosmetic Act, a drug's inclusion on the shortage list changes what compounding pharmacies may legally do — specifically the provisions covering compounded drugs that are "essentially a copy of a commercially available drug product" under section 503A and the bulk drug substance and essentially-a-copy rules under section 503B ^[1]. That is the legal hook that allowed a large compounded semaglutide market to grow while the shortage lasted.

FDA later acknowledged the scale of it, writing that "a substantial amount of semaglutide compounding is occurring" and that "some number of patients currently receiving those products can be expected to seek Novo Nordisk's approved products when compounding is curtailed" ^[1].

Why it matters for patients

The 2022 listing explains a lot of what US patients experienced afterward: pharmacies unable to fill certain pen strengths, prescribers switching people between doses based on what was in stock, and a parallel market of compounded semaglutide that existed largely because the brand was listed as short.

FDA also drew a distinction that matters at the counter. A resolved national shortage does not guarantee every pharmacy has every strength. The agency said intermittent problems are "most likely explained not by a continuing national shortage of supply, but by the practical dynamics of the part of the supply chain between Novo Nordisk and the firm's customers, including wholesale distributors and pharmacies" ^[1].

What happens next

The shortage era formally closed in 2025. FDA's February 21, 2025 order gave state-licensed pharmacists and physicians compounding under section 503A until April 22, 2025, and outsourcing facilities under section 503B until May 22, 2025, before the agency would consider enforcement action tied to shortage-based compounding ^[1]. FDA said it will "continue to monitor supply and demand for these products" and may relist them if warranted ^[1].